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ABSTRACT
Invasive fungal infections (IFIs) are now the main cause of death from infection in cases of allogeneic
stem-cell transplantation and an important cause of morbidity and mortality in patients with
haematological malignancies undergoing chemotherapy. Their prevention is one of the major objectives
of anti-infective support programmes for onco-haematology patients. Fluconazole is safe and effective as
prophylaxis for Candida infections in allogeneic stem-cell transplant (SCT) patients, although for non-
SCT onco-haematology patients, its role has not been established, in spite of its very frequent use in
clinical practice. After more than 10 years of massive use of ﬂuconazole prophylaxis, there are several
controversies in relation to its use. The emergence of resistant pathogens, the shift in the epidemiology of
the main fungal pathogens, interactions among antifungal and non-antifungal drugs, organ toxicities
and cost are some of the problematic issues, and similar problems should be expected with new drugs.
Nowadays, the main IFI organisms in onco-haematology patients and the cause of the majority of
fungal-related deaths are not Candida but Aspergillus species. Consequently, interest in fungal
prophylaxis has moved from prevention of Candida infections to prevention of infections caused by
Aspergillus, against which ﬂuconazole has no activity. Itraconazole, administered as an oral solution or
intravenously, but not as capsules, is an effective chemoprophylaxis for Aspergillus if the patient can
tolerate the drug. New drugs, new prophylactic strategies and new forms of drug administration are
under study and are reviewed in this article.
Keywords Acute leukaemia, antifungal chemoprophylaxis, Aspergillus, Candida, invasive fungal
infection, myelosuppressive chemotherapy, neutropenia, stem-cell transplantation
Clin Microbiol Infect 2006; 12 (suppl 7) : 65–76
INTRODUCTION
Invasive fungal infections (IFIs) are now the main
cause of death from infection in cases of alloge-
neic stem-cell transplantation, and this represents
a major change in the context of transplant
mortality. At the end of the 1980s, cytomegalovi-
rus (CMV) was the main cause of death from
infection; as many as 20% of patients died
because of CMV disease. The development of
effective prevention, based on either prophylactic
or pre-emptive therapy, dramatically reduced
CMV-associated mortality and elevated IFI to
ﬁrst place among deadly infectious diseases. IFIs
are also an important cause of morbidity and
mortality in patients with haematological malig-
nancies, mainly acute leukaemia and myelod-
ysplastic syndromes, who are undergoing
chemotherapy. The high rate of mortality (50–
90%) associated with these infections has
remained essentially unchanged for the last
30 years, particularly for mould infections [1–3].
Not surprisingly, but quite disappointingly, the
proportion of patients without a clinical diagnosis
of invasive aspergillosis but with evidence of
disease at autopsy (68%) has remained
unchanged for 40 years (1953–1992) [4,5]. It is
very difﬁcult, or impossible, to cure what we do
not suspect exists. Nowadays, mortality due to
IFI, even with the new antifungal agents, is
unacceptably high. Voriconazole, one of the great
advances in the antifungal armamentarium and
now the front-line treatment of choice for invasive
aspergillosis, has little more than a 50% chance of
overall success [6], a response rate that decreases
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to 32% for allogeneic stem-cell transplant (SCT)
patients. Clearly, therefore, there is room for
improvement.
The prevention of IFI has been a major objective
in the supportive care of cancer and SCT patients,
and has been approached in different ways
historically. In the 1970s, strict infection control
and protective environment interventions were
the backbone of the anti-infective prevention
strategy. In the 1980s, empirical antifungal ther-
apy for persistent febrile neutropenic patients, an
early form of antifungal therapy, became very
popular after the publication of the study by
Pizzo et al. [7], and now it is considered standard
practice [8]. In the early 1990s, the introduction of
ﬂuconazole [9] marked the beginning of a new era
in the prevention of IFI.
The great majority of IFIs in onco-haematology
and SCT patients are due to Candida spp. and
Aspergillus spp., so they have been the main
targets of all preventive measures. This article
reviews the subject of chemoprophylaxis with
systemic antifungal agents in patients with haem-
atological malignancies and in SCT patients.
GENERAL CONSIDERATIONS
Non-absorbed oral agents, e.g., clotrimazole, mic-
onazole, amphotericin B and nystatin, which may
reduce superﬁcial mycoses but not IFI [10–12], are
not discussed further. Nonetheless, prophylaxis
of superﬁcial candidiasis may be justiﬁed,
because colonisation of two independent anatom-
ical regions is a documented risk-factor for inva-
sive candidiasis in onco-haematology patients.
There are four basic aspects to be considered in
relation to antifungal prophylaxis (Table 1).
Selection of the patient population that should
receive prophylaxis
Only patients with high (or at least moderate) risk
of acquiring an IFI should receive chemoproph-
ylaxis. Patients clearly at high risk are those who
receive an allogeneic SCT, and patients with acute
leukaemias receiving myelosuppressive chemo-
therapy. Patients at low risk of IFI, e.g., those with
lymphoma receiving conventional chemotherapy,
should not receive antifungal prophylaxis
[8,13,14]. The deﬁnition of the population at high
risk of IFI is out of the scope of this review;
however, several risk-assessment schemes are
useful for the a priori categorisation of patients
according to risk [14,15] and can be used to
achieve appropriate risk-based antifungal pro-
phylaxis.
The epidemiology of IFI in speciﬁc patient
populations
It is essential to recognise the main fungal
pathogens and their incidence in the particular
patient population that we manage. Knowledge
of the main types of IFI determines the most
appropriate drug, based on its spectrum of
activity. The incidence of IFI indicates the overall
beneﬁt that can be expected; the greater the basal
incidence, the greater the probable beneﬁt. More-
over, if the basal incidence is low, it is difﬁcult to
prove the beneﬁts of any antifungal prophylaxis,
even if they exist. From the experience of more
than 50 randomised studies of antifungal pro-
phylaxis, the beneﬁt of prophylaxis is usually
demonstrable when the basal IFI incidence is ‡10–
20%; it is difﬁcult, however, to show a beneﬁt
when the incidence is between 5% and 10% (this
requires studies with a high number of patients);
and there is no visible beneﬁt when the incidence
is below 5%.
Selection of the appropriate antifungal agent
and dosage
Several characteristics of an antifungal agent have
to be taken into consideration: its spectrum of
activity, efﬁcacy, route of administration, toler-
ance, drug interactions and cost. As important as
knowledge of the fungal pathogens covered by
the drug is knowledge of those not covered. This
Table 1. Basic aspects of antifungal prophylaxis
1. Patient selection: only patients at high risk of IFI
2. The fungus itself: knowledge of its epidemiology
3. The antifungal:
Considerations: spectrum of activity, efﬁcacy, route of
administration, tolerance, drug interactions and cost
Appropriate dosage: basic for efﬁcacy:
Fluconazole: 400 mg ⁄day
Itraconazole: 400 mg ⁄day of oral solution or
200 mg ⁄day intravenously
4. Administration (when and how long)
Easy to determine in pure myelosuppressive therapy
More difﬁcult to determine in immunosuppressive
therapies (allogeneic SCT)
IFI, invasive fungal infection; SCT, stem-cell transplant.
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dual consideration has implications for the selec-
tion of resistant pathogens according to changes
in epidemiology and for the empirical manage-
ment of the suspected breakthrough infection that
may develop during prophylaxis. Good examples
of this, although controversial [12,16,17], are the
shift to non-albicans species of Candida associated
with ﬂuconazole prophylaxis [18–20] and the
increase of zygomycosis related to the use of
voriconazole [21].
Convenient administration of the drug is an
important aspect of all prophylactic regimens. For
antifungal prophylaxis, this usually means a drug
with both oral and intravenous formulations. At
present, only triazoles fulﬁl this requirement, and
that is one of the main reasons for their being ﬁrst
choice for antifungal prophylaxis.
Equally important as the selection of the most
appropriate antifungal agent is the determination
of an adequate dose, as there is a clear dose
dependency for efﬁcacy of the two main agents in
use, ﬂuconazole and itraconazole (Table 1). For
ﬂuconazole, 400 mg ⁄day is the recommended
dose in the main guidelines in use [8,13,22] and
in a meta-analysis of 16 trials of prophylactic
ﬂuconazole [23]. Nonetheless, some groups prefer
a dose of 200 mg ⁄day, and this is supported by
the results of a randomised trial that found no
differences in efﬁcacy between dosages of 400 mg
and 200 mg per day [24]. For itraconazole, a dose
of at least 400 mg ⁄day of oral solution or
200 mg ⁄day of intravenous solution is recom-
mended, based on the results of a meta-analysis
[25]. Capsules at 400 mg ⁄day or oral solution at
200 mg ⁄day proved not to be effective [25].
Drug interactions are an important aspect that
should be considered in all patients selected for
antifungal prophylaxis, particularly with triazole
compounds. Itraconazole [26] and voriconazole
[27] have more clinically relevant interactions
than ﬂuconazole in combination with other drugs.
With appropriate consideration, the management
of azoles is easily mastered [28].
Patient co-morbilities, particularly liver and
renal dysfunctions, and the safety proﬁle of the
antifungal agent are important considerations in
the selection of the drug. Clinicians know very
well that all formulations of amphotericin B are
nephrotoxic, that azoles (particularly those that
are broad-spectrum) are associated with hepato-
toxicity, and that echinocandins are well-toler-
ated. Less well known is that liposomal
amphotericin B and ﬂuconazole are also associ-
ated with hepatotoxicity [29].
Decision of when and for how long antifungal
prophylaxis should be administered
Although the logical answer, during the period of
risk, is obvious, the application in practice is not so
easy. The period of risk varies according to the type
of pathogen and treatment, among other factors. In
acute leukaemias treated with highly myelosup-
pressive chemotherapy, neutropenia is the major
risk-factor for IFI; the period of risk is usually short
(3–4 weeks) and coincides with the period of
neutropenia. In patients undergoing immunosup-
pressive therapy in addition to myelosuppression,
such as allogeneic SCT, the period of risk is longer
(months) than the period of neutropenia, and
quantiﬁcation is much more difﬁcult than the
simple counting of neutrophils. SCT patients with
graft vs. host disease (GVHD) may experience
severe immunosupression for years. Conventional
daily antifungal prophylaxis can be administered
more or less easily for a period of weeks, but is not
practical for many months; thus, alternative
approaches are needed for these patients.
The time at which antifungal prophylaxis is
initiated also has implications for toxicity. It is
well-known, from the study of Marr et al. [30],
that itraconazole should be administered after the
termination of chemotherapy, because of in-
creased liver toxicity when it is given concomit-
antly with high-dose cyclophosphamide. This
toxicity seems to result from an interaction
between itraconazole and cyclophosphamide
metabolism [31]. A similar effect was described
for itraconazole and busulfan [32]. Fluconazole
also alters the metabolism of cyclophosphamide
[31,33], although no increase in liver toxicity has
been reported when it is used concomitantly. As a
general principle, these data advise against the
concomitant use of antifungal azoles and cyto-
chrome-metabolised cytotoxic agents such as
cyclophosphamide.
PREVENTION OF YEASTS, MOULDS
OR BOTH?
As explained in detail in other parts of this
supplement, in the last 20 years a marked change
has occurred in the epidemiology of IFI in onco-
haematology patients [5,34,35]. The main cause of
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IFI in onco-haematology patients and the reason
for the majority of fungal-related deaths are not
Candida but Aspergillus species.
It is important to look at what exactly is meant
by ‘prevention of IFI’ in the prophylactic studies,
and speciﬁcally to look separately for data con-
cerning yeasts and moulds. Fluconazole, a good
drug for yeast, is not effective in the prevention of
invasive aspergillosis, so when the main IFIs are
due to Aspergillus species, the use of ﬂuconazole
would be inappropriate. On the other hand,
itraconazole, although it is at least as effective as
ﬂuconazole in preventing Candida infections [36],
is not indicated for preventing only Candida
infections, as itraconazole is more toxic and less
well-tolerated than ﬂuconazole.
CANDIDA PROPHYLAXIS : THE
ADVANTAGES
Prophylaxis for Candida species is a favourable
situation for several reasons (Table 2). Its efﬁcacy
in cases of SCT is well-established on the basis of
good, randomised placebo-controlled trials [37,38]
(Table 3). Fluconazole has been administered until
engraftment [37], or until day +75 after transplant
[38]. These studies showed not only a dramatic
decrease in the incidence of IFI in SCT patients, but
also a signiﬁcant decrease in fungal-related mor-
tality [37,38] and, with longer periods of ﬂuconaz-
ole administration (until day +75), a decrease in
overall mortality [38] (Table 3). A long-term fol-
low-up study of the Slavin et al. trial [38] demon-
strated that the survival beneﬁt observed at day
+110 was maintained at 8 years [39]. This long-
term survival beneﬁt was attributed to a reduction
in candidiasis-related mortality [39]. It should be
noted that the survival advantage associated with
ﬂuconazole prophylaxis was signiﬁcant only in
allogeneic SCT recipients and not in cases of
autologous SCT [39]. There is no other trial that
has shown a survival advantage with antifungal
prophylaxis in the autologous setting.
The long-term follow-up study of Marr et al.
[39] has some inconsistencies with the original
study of Slavin et al. [38]. Although both included
exactly the same patient population, there was one
difference in patient sex, there were eight differ-
ences in the type of room used at transplantation
and, more important, the data for acute GVHD
were signiﬁcantly different between the studies. In
the original trial [38], a higher statistically signi-
ﬁcant incidence of acute GVHD (grades 2–4) was
associated with ﬂuconazole prophylaxis. The
authors pointed out in the discussion that the
same ﬁnding was made previously in the trial of
Goodman et al. [37]. However, in the follow-up
study [39], although the incidence of acute GVHD
(grades 2–4) was higher in the ﬂuconazole arm, the
difference was, surprisingly, not statistically sig-
niﬁcant. Moreover, ﬂuconazole prophylaxis was
associated with a statistically signiﬁcant reduced
incidence of severe gut GVHD (grades 3–4).
Finally, it is difﬁcult to understand how prophy-
laxis during the ﬁrst 75 days can decrease mortal-
ity due to invasive candidiasis and related deaths
up to 2 years later. Thus, as there is no other study
that has reproduced this increase in survival with
ﬂuconazole prophylaxis, this aspect of the Slavin
et al. study [38], although impressive, should be
regarded with caution.
CANDIDA PROPHYLAXIS : THE
DISADVANTAGES
After more than 10 years of widespread ﬂucon-
azole prophylaxis, with thousands of patients
Table 2. Candida prophylaxis: the optimal situation
1. The fungus is susceptible to a broad range of
antifungal agents
2. The high-risk period is usually short (weeks)
Candida is typically a pathogen of the neutropenic period
3. An antifungal agent of choice exists: ﬂuconazole
Convenient administration
Well-absorbed and tolerated
Few signiﬁcant drug interactions
Inexpensive
Very effective (in SCT patients)
SCT, stem-cell transplant.
Table 3. Candida prophylaxis with ﬂuconazole in stem-cell
transplant patients
Study No. Fluconazole Placebo p
IFI incidence (%)
Goodman et al. [37] 356 2.8 15.8 <0.001
Slavin et al. [38] 300 7 18 0.004
IFI-related mortality (%)
Goodman et al. [37] 356 0.5 5.6 0.001
Slavin et al. [38] 300 13 21 0.005
Overall mortality (%)
Goodman et al. [37] 356 31 26 0.38
Slavin et al. [38] 300 20 35 0.004
Marr et al. [39] 300 55 73 0.0001
IFI, invasive fungal infection.
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enrolled in trials, there are several important
controversial issues and clear shortcomings.
For non-SCT onco-haematology patients, the
prophylactic role of ﬂuconazole has not been
established, in spite of its very frequent use in
clinical practice. A meta-analysis of 16 trials with
3734 patients failed to show an effect of ﬂucon-
azole prophylaxis on either fatal fungal infection
or systemic fungal infection in non-SCT patients
[23]. This may be explained by the lower inci-
dence of IFI in non-SCT patients (0–7.6%) com-
pared with SCT patients (15.8 vs. 17.6%).
First of all, even for allogeneic SCT patients,
one wonders whether ﬂuconazole prophylaxis is
always necessary in spite of its demonstrated
efﬁcacy for Candida prevention. The answer will
depend on the basal frequency of Candida infec-
tions in the patient population, as the beneﬁts of
prophylaxis depend on this. A good example is
the study reported by Jantunen et al. [40]. In 685
allogeneic SCT patients managed without any
systemic antifungal prophylaxis, the incidence of
invasive candidiasis was very low (1.3%). This
incidence is lower than the combined incidence
(2.1%) of patients receiving prophylaxis with
ﬂuconazole in the two main randomised studies
mentioned earlier [37,38]. So, if the basal inci-
dence is low in the patient population (even
allogeneic SCT patients), ﬂuconazole prophylaxis
seems not to be necessary.
One important shortcoming of ﬂuconazole pro-
phylaxis relates to its limited spectrum of activity.
Particularly signiﬁcant is the lack of activity
against Aspergillus, Candida krusei and some strains
of Candida glabrata. Although the trials of prophy-
lactic use of ﬂuconazole have not demonstrated an
increased incidence of invasive aspergillosis or
other moulds, there is some other evidence that
supports this case [34,35,41]. In an autopsy-based
study of 355 SCT patients, ﬂuconazole prophylaxis
proved to be associated with a 60% increase in
invasive aspergillosis, according to univariate and
multivariate analyses [41]. This is the most direct
evidence of the effect of ﬂuconazole prophylaxis in
the shift towards aspergillosis as the most frequent
cause of IFI. Two studies ﬁxed 1989 as, more or
less, the year of the beginning of the shift from
Candida to Aspergillus species as the most frequent
cause of IFI [34,35], which coincides with the
introduction of ﬂuconazole into the market. In a
large Japanese study of 594 263 autopsies, the
predominant causative agent for severe mycotic
infection shifted from Candida to Aspergillus dur-
ing the period 1989–1994 [34]. One of the possible
reasons for the shift could be the introduction of
ﬂuconazole into the Japanese market in 1989. A US
study of multiple-cause-of-death records from the
National Center of Health Statistics from 1980 to
1997 found that a 50% decrease in candidiasis and
a 350% increase in aspergillosis had occurred
since 1989 [35]. This also coincides temporally
with the introduction of ﬂuconazole into the USA
in 1990. There are several possible explanations for
the association between ﬂuconazole use and
increased risk of mould infections [42]. One
obviously disturbing possibility is the biological
alteration of the offending opportunistic Aspergil-
lus strain following exposure to ﬂuconazole,
resulting in an antagonism with subsequently
administered amphotericin [43] and even an
attenuation of the fungicidal activity of voricon-
azole [44].
Today, 50% of the infections caused by Candida
are due to non-albicans species [45]. Fluconazole
has been related to this species shift [18–20],
although it has also occurred in patients who did
not receive ﬂuconazole prophylaxis [12,46,47].
In a double-blind, controlled, single-centre trial,
ﬂuconazole was associated with prolonged severe
neutropenia (p 0.01) [48]. This adverse event has
not been reported in other trials, so its signiﬁcance
is doubtful.
Prophylaxis against one type of pathogen can
have a negative impact on other types of patho-
gens, e.g., the association between a higher
incidence of bacteraemia and antifungal prophy-
laxis, particularly oral triazoles [49,50].
ASPERGILLUS SPP . PROPHYLAXIS
Invasive aspergillosis is the main cause of IFIs in
onco-haematology and SCT patients, and its
prevention is now the main concern. In acute
leukaemia patients undergoing chemotherapy
and in autologous SCT patients, invasive asper-
gillosis is a disease of the pre-engraftment phase,
since 90% of the patients are neutropenic at
diagnosis. However, in allogeneic SCT patients, it
is a post-engraftment complication, as only 30%
of the patients are neutropenic at diagnosis [51].
The main epidemiological difference in invasive
aspergillosis in the allogeneic SCT setting is a shift
of presentation to the late phase of the transplant
(more than 6 months), which highlights the
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importance of the non-neutropenic immunosup-
pressed state in the pathogenesis of this disease
[52]. Aspergillus prophylaxis is a more difﬁcult
task than Candida prophylaxis (Table 4).
Itraconazole
Two other reviews in this supplement discuss
itraconazole, and thus it is not analysed in detail
here. There is considerable experience with this
drug in antifungal prophylaxis in onco-haematol-
ogy patients. There are three main studies that
support its efﬁcacy in prophylaxis: two random-
ised blind studies comparing itraconazole with
ﬂuconazole [30,53], and one meta-analysis that
included 16 randomised studies with a total of
3597 patients [25]. This evidence shows that
itraconazole is effective in the overall prevention
of IFIs and also invasive aspergillosis. No other
marketed antifungal drug has been effective in
preventing invasive aspergillosis until now [25].
Nowadays, itraconazole is the better choice for
preventing invasive aspergillosis. A basic require-
ment for the prevention of Aspergillus infections is
the use of an appropriate dosage, as noted before.
Amphotericin B
Conventional intravenous amphotericin B is
poorly tolerated and has never been regarded as
a good option for prophylaxis. Two randomised
double-blind placebo-controlled studies were
conducted with an ultra-low dose of conventional
amphotericin B (0.1 mg ⁄ kg ⁄day) [54,55]. One of
the studies had too few patients to make it useful
for analysis [55] and the other demonstrated no
beneﬁt over placebo [54]. Conventional ampho-
tericin B was compared with ﬂuconazole in two
randomised non-blinded trials, which found that
amphotericin B was no more effective than
ﬂuconazole but clearly more toxic [56,57].
The lipid formulations of amphotericin B are
clearly less toxic than conventional amphotericin
B but have not shown a signiﬁcant effect in the
prevention of IFI. Two randomised double-blind,
placebo-controlled studies with liposomal amph-
otericin B demonstrated no beneﬁt over placebo
[58,59]. An unusually designed study compared
liposomal amphotericin B with a combination of
ﬂuconazole and an ineffective dose of itraconaz-
ole [60]. Liposomal amphotericin B was no more
effective than the azole combination, but was
more toxic [60]. An open-label randomised trial
comparing amphotericin B colloidal dispersion
with ﬂuconazole was prematurely stopped
because of the severe toxicity associated with
amphotericin B infusion [61].
In summary, no published evidence supports
the use of conventional or lipid formulations
of amphotericin B for fungal prophylaxis.
Nonetheless, a meta-analysis that included four
placebo-controlled randomised trials concluded
that prophylactic intravenous amphotericin
B prevents invasive fungal infection, but not
invasive aspergillosis, overall mortality or fungal-
related mortality [62]. An unpublished rand-
omised phase III trial compared liposomal
amphotericin B (50 mg every other day) with no
antifungal prophylaxis, (Penack O, et al. Low dose
Liposomal Amphotericin B (L-AmB) as Prophy-
laxis of Invasive Fungal Infection (IFI) in Patients
(pts) with Prolonged Neutropenia (N): Results
from a phase-III Trial. 45th Annual Interscience
Conference on Antimicrobial Agents and
Chemotherapy (ICAAC), 2005 Washington. 2005:
abstract M-975) and found a lower incidence of
proven or probable IFI (4.6% vs. 20.2%, p 0.001)
and less use of systemic antifungal agents (22% vs.
59%, p 0.001), but no differences in mortality or
liver or renal abnormalities associated with lipo-
somal amphotericin B. Both previously mentioned
meta-analyses [62] and the unpublished study of
Penack et al. leave open the possibility of liposomal
amphotericin B for antifungal prophylaxis.
Echinocandins
Echinocandins are only suitable for short periods
of prophylaxis, mainly during neutropenia, as
they can only be given intravenously. In their
Table 4. Aspergillus prophylaxis: a complicated situation
Compared to Candida prophylaxis:
1. The fungus is susceptible to a narrow range of antifungal
agents
2. The high-risk period can be very long
In allogeneic SCT patients, Aspergillus is a pathogen of
the post-engraftment period
3. Antifungal candidates
Convenient administration: only itraconazole and
voriconazole
Frequent drug interactions: azoles > echinocandin >
amphotericin B
More expensive
Less effective
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favour, these compounds cover Candida and
Aspergillus species, the main fungal pathogens in
onco-haematology patients; they are well-toler-
ated and present few signiﬁcant clinical drug
interactions [27]. The prophylactic studies
performed with these drugs, until now, have not
been very impressive.
Caspofungin was compared with intravenous
itraconazole in a randomised, open-label study,
[63]. Prophylaxis was administered only during
neutropenia (median 21 days), in 192 patients
receiving induction chemotherapy. There was no
difference between groups in the incidence of
proven or probable IFI (5.8% in the itraconazole
group vs. 6.6% in the caspofungin group), mor-
tality or adverse events.
Micafungin was compared with intravenous
ﬂuconazole during neutropenia in a randomised,
double-blind trial involving 882 SCT patients [64].
There was no difference in the incidence of
proven or probable IFI (1.6% vs. 2.4%, p 0.48),
invasive aspergillosis (0.2% vs. 1.5%, p 0.07),
candidaemia (0.9% vs. 0.4%, p 0.43), mortality
(4.2% vs. 5.7%, p 0.32) or adverse events between
micafungin and ﬂuconazole, respectively. The
only positive effect associated with micafungin
prophylaxis was lower use of empirical antifungal
therapy (15.1% vs. 21.4%, p 0.02).
Second-generation triazoles
There is great interest in the employment of
voriconazole and posaconazole for antifungal
prophylaxis, as they have a broad spectrum of
activity and are available in oral formulation.
Voriconazole also has an intravenous formulation
that makes it suitable for use during periods of
gastrointestinal intolerance or mucositis. No data
concerning the use of voriconazole in prophylaxis
are available yet. There is an ongoing random-
ised, double-blind trial comparing voriconazole
with ﬂuconazole for 100 days (or 180 days in
high-risk situations) in 600 allogeneic SCT
patients [65]. This study will clarify whether there
is an increased risk of zygomycosis associated
with voriconazole prophylaxis.
Recently, an exciting study was communicated
in a preliminary form (Ullmann AJ, et al. Posaco-
nazole (POS) vs Fluconazole (FLU) for prophy-
laxis of Invasive Fungal Infections (IFIs) in
Allogenic Hematopoietic Stem Cell Transplant
(HSCT) Recipients with Graft-versus-Host Dis-
ease (GVHD): Results of a Multicenter Trial. 45th
Annual Interscience Conference on Antimicrobial
Agents and Chemotherapy (ICAAC), 2005
Washington. 2005: abstract M-716). This was a
randomised, double-blind trial comparing oral
posaconazole with ﬂuconazole for prophylaxis in
600 allogeneic SCT patients with GVHD under-
going intensive immunosuppressive therapy.
This is one of the populations at highest risk for
IFI, so the drugs were tested in a very demanding
scenario. Antifungal prophylaxis started when
the patient had acute GVHD (grade 2–4) or
extensive chronic GVHD and was undergoing
intense immunosuppressive therapy for up to
16 weeks. The preliminary data are shown in
Table 5 and are quite impressive. Posaconazole
appeared to be superior to ﬂuconazole in pre-
venting invasive aspergillosis, and at least as
effective in preventing other breakthrough IFIs.
Posaconazole tolerance was good and similar to
that of ﬂuconazole, an interesting fact, as ﬂucon-
azole is the least toxic of the available systemic
antifungal agents. Pending publication of this
trial, posaconazole is moving towards being
regarded as a priority choice in cases of high-risk
allogeneic SCT.
Table 5. Posaconazole prophylaxis
vs. ﬂuconazole prophylaxis in allo-
geneic stem-cell transplant patients
with graft vs. host disease undergo-
ing intense immunosuppressive
therapy
Posaconazole Fluconazole OR p
Total IFI (at 16 weeks)
primary endpoint
5% 9% 0.56 0.07
Total IFI (at 24 weeks) 7% 14% 0.43 0.003
Invasive aspergillosis
(at 16 weeks)
2% 7% 0.31 0.006
Breakthrough IFI 2% 8% 0.30 0.004
Overall mortality 25% 28 NS
IFI-related mortality 1% 4% 0.046
Discontinuation due
to adverse events
33% 33% NS
IFI, invasive fungal infection; NS, not signiﬁcant.
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OTHER FORMS OF ANTIFUNGAL
PROPHYLAXIS
New forms of prophylaxis
Time-targeting vs. risk-targeting strategies
Traditionally, antifungal prophylaxis in onco-
haematology patients has been what we could
call a ‘time-targeting’ strategy. It is given during a
ﬁxed period, starting at a ﬁxed time, focusing on
covering the neutropenic period. This strategy
covers reasonably well a patient population in
which IFI is mainly associated with neutropenia,
e.g., acute leukaemias or myelodysplastic syn-
dromes treated with intensive myelosuppressive
therapy and the majority of cases of autologous
SCT. In allogeneic SCT patients, one of the groups
at highest risk for IFI, the majority of IFIs occur
outside the period of neutropenia, highlighting
the importance of the non-neutropenic immuno-
suppressed state in the pathogenesis of IFI. Except
for Candida and Scedosporium species, more than
70% of the main IFIs occur after day 40 [66].
Prophylaxis targeting the period of GVHD result-
ed in very positive results in a recent trial
(Ulmann Aj, et al. 45th Annual Interscience Con-
ference on Antimicrobial Agents and Chemother-
apy (ICAAC), 2005 Washington. 2005: abstract
M-716) and in another small study [67]. Reason-
ably, this ‘risk-targeting’ strategy could be com-
plemented with a traditional ‘time-targeting’
strategy, during the neutropenic period, to achieve
optimal antifungal coverage in high-risk patients.
Prophylactic aerosolised amphotericin B inhalation
Because invasive aspergillosis is usually acquired
by inhalation of Aspergillus conidia and the lungs
are the primary site of infection, the use of
prophylactic amphotericin B inhalation is appeal-
ing. Although use of prophylactic conventional
amphotericin B inhalation was associated with
beneﬁt in some uncontrolled single-arm studies
[68–71], it was found not to be effective in a large
multicentre randomised trial in neutropenic
patients [72]. Based on the result of this trial,
the use of nebulised amphotericin B deoxycho-
late was abandoned in neutropenic patients. In
recent aerosol studies, lipid formulations of
amphotericin B proved to be safe and better
tolerated than amphotericin B deoxycholate in
lung transplant patients [73,74]. No amphotericin
B can be detected in serum after aerosol admin-
istration of conventional or lipid formulations
[73,75]. An advantage of the lipid formulation
over conventional amphotericin B is the much
longer persistence in bronchoalveolar ﬂuid. In a
recent study communicated in a preliminary
form (Monforte V, et al. Pharmokinetics and
Efﬁcacy of Nebulized Ambisome (n-Amb) in
lung transplantation (Lt). 44th Annual Inter-
science Conference on Antimicrobial Agents
and Chemotherapy (ICAAC), Washington. 2004:
abstract M-1042), signiﬁcant concentrations of
amphotericin B (6.6 mg ⁄L) were detected 14 days
after a nebulised dose of liposomal amphotericin
B. This offers the possibility of a very convenient
form of administration (once-weekly) for long-
term prophylaxis in onco-haematology patients.
The preliminary data concerning this approach
were reported recently (Ruiz I, et al. Safety and
Tolerability of Nebulized Liposomal Amphoteri-
cin B in Hematologic patients. 45th Annual
Interscience Conference on Antimicrobial Agents
and Chemotherapy (ICAAC), 2005 Washington.
2005: abstract M-977) .
High-dose intermittent liposomal amphotericin B
An interesting pharmacokinetic study (Gubbins
PO, McConnell SA, Amsden JR, Anaissie E.
Comparison of Liposomal Amphotericin B Plasma
and Tissue Concentrations following a single
Table 6. Other prophylactic meas-
uresAvoiding What do we achieve?
Antibacterial chemoprophylaxis Decrease in invasive candidiasis [76–78]
Ganciclovir prophylaxis Decrease in global IFI (16% to 6%) [79]
Graft T-cell depletion Decrease in fatal aspergillosis
(16% to 6%] [80]
Respiratory virus infections Decrease in invasive aspergillosis
(HR 2.1) [52]
CMV disease Decrease in invasive aspergillosis (HR 7) [52]
IFI, invasive fungal infection; CMV, cytomegalovirus; HR, hazard ratio.
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large (15 mg/kg) Dose or daily 1 mg/kg Dosing.
44th Annual Interscience Conference on Anti-
microbial Agents and Chemotherapy (ICAAC),
Washington. 2004: abstract A-33) communicated
in a preliminary form compared plasma and
tissue concentrations following a large single dose
(15 mg ⁄ kg) or a low daily dose of 1 mg ⁄kg for
15 days in 11 SCT patients. For tissue sampling, a
mucosal biopsy specimen was obtained on days 7
and 15 of treatment. There were no differences in
tissue concentrations and creatinine in the single-
large-dose vs. daily low-dose groups. At day 15
post-treatment, the mean concentrations in tissue
were 12.1 mg ⁄ kg and 16.6 mg ⁄ kg, respectively.
These results suggest a practical long-term regi-
men for intravenous prophylaxis. Clinical studies
are needed, as there is no available information
concerning the efﬁcacy and safety of this
approach in a large number of patients.
OTHER PROPHYLACTIC MEASURES
Other measures have a signiﬁcant impact on the
risk of IFI, even greater than antifungal prophy-
laxis (Table 6). Some of these measures include
chemoprophylaxis for other types of pathogens,
or the indirect effect of some viruses (e.g., CMV,
respiratory virus), showing how interrelated and
complex the infectious complications of onco-
haematology patients can be. When thinking
about administering chemoprophylaxis for a
speciﬁc pathogen, the possibility of inducing a
change, not always in a good direction, in other
apparently unrelated pathogens must be remem-
bered.
CONCLUSIONS
The prevention of IFIs is one of the major
objectives of the anti-infective support of onco-
haematology patients. Graded recommendations,
based on the criteria of the CDC [13], are shown
in Table 7. Fluconazole proved, more than a
decade ago, to be safe and effective as prophy-
laxis for Candida infections in allogeneic SCT
patients. However, after more than 10 years of
its widespread use, there have been, until now,
controversies in relation to the best means of
antifungal prophylaxis. The interest in fungal
prophylaxis has moved from Candida to Asperg-
illus prevention, where ﬂuconazole has no activ-
ity. Itraconazole, in oral solution or intravenous
form, is the drug with most published evidence
of efﬁcacy. New drugs such as the second-
generation triazoles, particularly voriconazole
and posaconazole, new prophylactic strategies
(‘risk-targeting’ instead of ‘time-targeting’), and
new forms of antifungal delivery, e.g., inhalation
and high-dose intermittent intravenous adminis-
tration, are some of the promising possible
solutions for improved prevention of IFI in the
coming years.
Table 7. Antifungal prophylaxis in onco-haematology patients
Drug Graded recommendation
Indication based
on clinical studies Comments
Fluconazole AI: for allogeneic SCT Narrow: Candida No activity against moulds
CI: for the rest of patients
Itraconazole BI Broad: yeast and moulds Decreased incidence of
invasive aspergillosis
Voriconazole No data available No data available Studies ongoing
Posaconazole A ⁄B? I for high-risk allogeneic SCT Broad: yeast and moulds Decreased incidence of
invasive aspergillosis
(unpublished data)
Conventional
amphotericin
DI No better than ﬂuconazole
but more toxic
Liposomal
amphotericin
CI Narrowa: Candida No beneﬁt over placebo
and expensive
ABCD DI Toxic and expensive
Echinocandins CI Narrowa: Candida No better than ﬂuconazole
but more expensive
aThe spectrum of activity of the antifungal agent is broad but it was classiﬁed as narrow according to the clinical efﬁcacy in
trials.
ABCD, amphotericin B colloidal dispersion.
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